Ask AI
ProCE Banner Activity

OASIS-4: Phase III Trial of Elinzanetant for Vasomotor Symptoms Associated With Endocrine Therapy in Patients With or at Risk for HR+ Breast Cancer

Conference Coverage
Slideset

In the phase III OASIS-4 trial, elinzanetant significantly reduced the frequency of vasomotor symptoms vs placebo in women with or at risk for HR+ breast cancer receiving endocrine therapy, with a sustained effect throughout the duration of the study.

Released: June 06, 2025

Expiration: December 05, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.